Skip Navigation

Clinical Trials

Clinical trials are health-related studies in people that are closely supervised and carefully follow a pre-defined protocol. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose or treat a disease. Clinical trials may be done to see how a new treatment compares with the standard  clinical trialstreatment or to see if a new treatment is safe and effective for a certain condition or disease. Participation in this type of research involves treatment with an experimental treatment or medical device, which may or may not provide a direct benefit to the individual. A clinical trial must be conducted for all new treatments before the FDA will approve the treatment for the public. The Emory ALS Center is actively engaged in research projects involving clinical trials of new medications to slow the progression of ALS. Search for clinical trials www.clinicaltrials.gov

ALS patients have never had as many opportunities to participate in research projects as they have today.

Clinical Trials Opportunities: (treatment with an experimental drug)

Acthar: ENROLLING--This phase 2 placebo-controlled trial sponsored by Mallinckrodt will test the safety, tolerability, and pharmacokinetics of an investigational injectable drug in patients with ALS. Click here for complete information. Contact Janet Brantley at 404-727-1673  or janet.m.brantley@emory.edu .

Centaur: ENROLLING-- Amylyx Pharmaceuticals is offering a phase II trial investigating the safety and tolerability of a new combination of drugs (already FDA approved for other diseases) in ALS.  Click here for complete information. Contact Janet Brantley at 404-727-1673 or janet.m.brantley@emory.edu .

Single and Multiple Dose Study of BIIB067: ENROLLING--This is a Phase 1 placebo-controlled study from Biogen. Click here for eligibility and information. Contact Anna Partlow at 404-778-3181 or apartlo@emory.edu.

FORTITUDE Study: ENROLLING —Cytokinetics is sponsoring a study to assess safety and tolerability of CK-2127107 in patients with ALS. Click here for complete information. Contact Meraida Polak, RN at 404-778-3807 or mpolak@emory.edu.

Genentech GDC-0134:  ENROLLING--This is a first-in-human study to examine whether the drug GDC-0134 is safe and tolerable in people with ALS. Click here for complete study information. Contact Jane Bordeau, RN at 404-727-1679 or jrbord@emory.edu .

OrionPharma Trial of Levosimendan in ALS (RefALS): ENROLLING SOON-- OrionPharma is sponsoring a Phase 3 study of the drug levosimendan in people with ALS. Levosimendan is an FDA-approved medication for heart failure that acts by causing the heart muscle to beat more strongly. Click here for more information. Contact Jane Bordeau at jrbord@emory.edu.

HAVE YOU ENROLLED IN THE NATIONAL ALS REGISTRY??

registry

www.alsa.org/als-care/als-registry  

Done